WeVote
Log In

Bill

Bill

S 3188

Biomanufacturing Excellence Act of 2025

119th Congress Introduced by Ted Budd and 1 co-sponsor

S 3188 establishes federal biomanufacturing infrastructure, funding, and workforce development to boost domestic production of biotech-derived medicines and chemicals competitively.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 3188

Legislative bill overview

The Biomanufacturing Excellence Act of 2025 establishes a coordinated federal strategy to advance domestic biomanufacturing capabilities, including funding for research infrastructure, workforce development, and public-private partnerships. The bill aims to position the United States as a global leader in converting biological materials into medicines, chemicals, and industrial products through biotechnology.

Why is this important

Biomanufacturing is critical infrastructure for producing vaccines, therapeutics, and sustainable alternatives to petroleum-based chemicals. Strengthening domestic capacity reduces dependence on foreign supply chains for essential medicines and strengthens economic competitiveness in a rapidly growing bioeconomy sector worth tens of billions annually.

Potential points of contention

  • Funding allocation and fiscal concerns: The bill likely requires significant federal investment; fiscal conservatives may question costs while supporters argue it's necessary for national competitiveness versus China and Europe.
  • Regulatory clarity: Creating new manufacturing standards and oversight may face opposition from industry groups worried about compliance burdens, while safety advocates may push for stricter standards.
  • Public-private partnership structure: Questions may arise about how much taxpayer support flows to private companies and whether intellectual property arrangements adequately benefit the public.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.